| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mirijam Fric, Gerd Lau. [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Psychiatrische Praxis. vol 30. issue Suppl 2. 2019-11-20. PMID:13130349. |
[prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine] elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine d2 receptor antagonism. |
2019-11-20 |
2023-08-12 |
Not clear |
| Unax Lertxundi, Saioa Domingo-Echaburu, Javier Peral, Montserrat Garcí. Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe? Psychopharmacology bulletin. vol 44. issue 3. 2019-11-20. PMID:27738363. |
antipsychotic induced symptomatic hyperprolactinemia: are dopamine agonists safe? |
2019-11-20 |
2023-08-13 |
Not clear |
| Unax Lertxundi, Saioa Domingo-Echaburu, Javier Peral, Montserrat Garcí. Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe? Psychopharmacology bulletin. vol 44. issue 3. 2019-11-20. PMID:27738363. |
published literature shows that dopamine agonists can reverse antipsychotic-induced hyperprolactinemia without worsening psychotic symptoms in the majority of schizophrenic patients. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ebony T Gilbreath, Lakshmikripa Jaganathan, Madhan Subramanian, Priya Balasubramanian, Katrina D Linning, Sheba M J MohanKumar, Puliyur S MohanKuma. Chronic estrogen affects TIDA neurons through IL-1β and NO: effects of aging. The Journal of endocrinology. vol 240. issue 2. 2019-09-09. PMID:30400030. |
we hypothesized that chronic exposure to low levels of estradiol-17β (e2) can induce inflammatory and degenerative changes in the tuberoinfundibular dopaminergic (tida) system leading to reduced dopamine synthesis and hyperprolactinemia. |
2019-09-09 |
2023-08-13 |
mouse |
| Signe W Düring, Mette Ø Nielsen, Nikolaj Bak, Birte Y Glenthøj, Bjørn H Ebdru. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D Psychiatry research. vol 274. 2019-06-10. PMID:30780063. |
sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of d sexual side-effects along with antipsychotic treatment may be linked to hyperprolactinemia and dopamine d |
2019-06-10 |
2023-08-13 |
Not clear |
| Andrea Glezer, Marcello D Bronstei. Prolactinomas: how to handle prior to and during pregnancy? Minerva endocrinologica. vol 43. issue 4. 2019-03-21. PMID:29265784. |
treatment, usually with dopamine agonist (da), can reverse hyperprolactinemia and hypogonadism, allowing pregnancy in the majority of cases. |
2019-03-21 |
2023-08-13 |
Not clear |
| Adriana G Ioachimescu, Maria Fleseriu, Andrew R Hoffman, T Brooks Vaughan Iii, Laurence Katznelso. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. European journal of endocrinology. vol 180. issue 1. 2019-03-05. PMID:30400048. |
psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. |
2019-03-05 |
2023-08-13 |
human |
| Adriana G Ioachimescu, Maria Fleseriu, Andrew R Hoffman, T Brooks Vaughan Iii, Laurence Katznelso. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. European journal of endocrinology. vol 180. issue 1. 2019-03-05. PMID:30400048. |
background dopamine agonists (das) are the main treatment for patients with hyperprolactinemia and prolactinomas. |
2019-03-05 |
2023-08-13 |
human |
| Maya Barake, Anne Klibanski, Nicholas A Trito. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? European journal of endocrinology. vol 179. issue 6. 2018-12-11. PMID:30324793. |
dopamine agonists (das) represent a cornerstone in the management of patients with hyperprolactinemia and have an important role in the treatment of neurologic disorders, including parkinson's disease and restless legs syndrome. |
2018-12-11 |
2023-08-13 |
Not clear |
| Amit Akirov, Yona Greenman, Benjamin Glaser, Irena S'chigol, Yossi Mansiterski, Yoav Eizenberg, Ilana Shraga-Slutzky, Ilan Shimo. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary. vol 21. issue 4. 2018-10-16. PMID:29728863. |
hyperprolactinemia is common in acromegaly and in these patients, insulin-like growth factor (igf)-1 level may decrease with dopamine agonist. |
2018-10-16 |
2023-08-13 |
Not clear |
| Miao Yun Xia, Xiao Hui Lou, Shao Jian Lin, Zhe Bao W. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. vol 59. issue 1. 2018-10-01. PMID:29043560. |
optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. |
2018-10-01 |
2023-08-13 |
Not clear |
| Miao Yun Xia, Xiao Hui Lou, Shao Jian Lin, Zhe Bao W. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. vol 59. issue 1. 2018-10-01. PMID:29043560. |
dopamine agonists (das) are recommended as first-line treatment for patients with hyperprolactinemia. |
2018-10-01 |
2023-08-13 |
Not clear |
| Hiroshi Sato, Yuna Asami, Reona Shiro, Miki Yasuda, Saeko Imai, Rie Sakai, Kenji Oida, Kanako Kawaharamura, Nao Taguchi, Takako Suzuki, Masaya Hiros. Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 34. issue 3. 2018-08-27. PMID:28925774. |
resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. |
2018-08-27 |
2023-08-13 |
Not clear |
| Hiroshi Sato, Yuna Asami, Reona Shiro, Miki Yasuda, Saeko Imai, Rie Sakai, Kenji Oida, Kanako Kawaharamura, Nao Taguchi, Takako Suzuki, Masaya Hiros. Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 34. issue 3. 2018-08-27. PMID:28925774. |
a 45-year-old japanese woman, gravida 3 para 3, was referred to our hospital for further examination of hyperprolactinemia resistant to a dopamine agonist. |
2018-08-27 |
2023-08-13 |
Not clear |
| Hiroshi Sato, Yuna Asami, Reona Shiro, Miki Yasuda, Saeko Imai, Rie Sakai, Kenji Oida, Kanako Kawaharamura, Nao Taguchi, Takako Suzuki, Masaya Hiros. Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 34. issue 3. 2018-08-27. PMID:28925774. |
a prolactin-producing uterine leiomyoma should be considered as a possible cause of hyperprolactinemia resistant to dopamine agonists. |
2018-08-27 |
2023-08-13 |
Not clear |
| Hiroshi Sato, Yuna Asami, Reona Shiro, Miki Yasuda, Saeko Imai, Rie Sakai, Kenji Oida, Kanako Kawaharamura, Nao Taguchi, Takako Suzuki, Masaya Hiros. Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 34. issue 3. 2018-08-27. PMID:28925774. |
responsiveness to dopamine agonists; deterioration of hyperprolactinemia may be diagnostic for prolactin-producing uterine leiomyomas, although further research is required. |
2018-08-27 |
2023-08-13 |
Not clear |
| Roberto Salvator. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. vol 59. issue 1. 2018-06-18. PMID:29124662. |
dopamine agonist withdrawal in hyperprolactinemia: when and how. |
2018-06-18 |
2023-08-13 |
Not clear |
| Wei-Wei Sun, Lin-Yu Li, Xu-Feng Huang, Yan-Chuan Shi, He-Qin Yang, Zhi-Yuan Song, Shu Li. The central mechanism of risperidone-induced hyperprolactinemia. Progress in neuro-psychopharmacology & biological psychiatry. vol 76. 2018-04-02. PMID:28336493. |
furthermore, risperidone induced a decreased dopamine synthesis in the pvn and thus reduced the dopamine-induced inhibition of prolactin release, ultimately lead to hyperprolactinemia. |
2018-04-02 |
2023-08-13 |
mouse |
| Filip Gabalec, Jan Čáp, Jakub Radoch. [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists]. Vnitrni lekarstvi. vol 63. issue 9. 2018-02-20. PMID:29120651. |
[valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists]. |
2018-02-20 |
2023-08-13 |
Not clear |
| Filip Gabalec, Jan Čáp, Jakub Radoch. [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists]. Vnitrni lekarstvi. vol 63. issue 9. 2018-02-20. PMID:29120651. |
the paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease.key words: dopamine agonists - ergolines/adverse effects - heart valve diseases - hyperprolactinemia - pituitary neoplasms - prolactinoma. |
2018-02-20 |
2023-08-13 |
Not clear |